Pharaoh Neuro

Executive Summary

Pharaoh Neuro is an early-stage neurocritical care company developing its proprietary Neurapheresis™ platform, designed to restore and maintain cerebrospinal fluid (CSF) balance in patients with acute neurological injuries. CSF is critical for intracranial pressure regulation, metabolic waste clearance, and nutrient delivery; disruption can lead to catastrophic outcomes such as traumatic brain injury, subarachnoid hemorrhage, or stroke. The platform aims to transform neurocritical care by offering a targeted therapeutic approach to CSF dysregulation, potentially reducing mortality and improving neurological recovery. Founded in San Francisco and operating as a private entity, the company has limited public track record but addresses a significant unmet need in critical care neurology. Given the nascent stage of Pharaoh Neuro, conviction is moderate pending further clinical validation and disclosed milestones. The company has not yet reported fundraising totals, regulatory filings, or partnership announcements, but its focus on a novel mechanism in neurocritical care positions it as a high-risk, high-reward opportunity. Key near-term catalysts include initial clinical data from first-in-human studies, a Series A financing round to advance development, and potential strategic collaborations with major medical centers or industry players. Success will hinge on demonstrating safety and efficacy in early trials, securing regulatory pathway clarity, and attracting experienced leadership to navigate the complex neurocritical care landscape.

Upcoming Catalysts (preview)

• Q3 2026Initial Clinical Data Readout from Neurapheresis Feasibility Study40% success
• Q4 2026Series A Financing Round Completion60% success
• TBDStrategic Partnership with Major Neurocritical Care Center30% success